Hydroxycarbamide effect on DNA methylation and gene expression in MPN patients

Study

Study ID	Alternative Stable ID	Type
EGAS00001004583		Other

Study Description

Hydroxycarbamide (HC), is a cytoreductive drug frequently used to control cell blood counts in patients with myeloproliferative neoplasms (MPNs).To further explore the effects of HC in MPN patients, we performed DNA methylation and gene expression profiling of two differentially developed and clinically relevant cell types, both before and following HC exposure.

Study Datasets 3 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001006330	Whole RNA-sequencing of CD34+ cells and neutrophils derived from MPN patients before hydroxycarbamide treatment and after 9-months of treatment. CD34+ cells= 5 patients, 10 samples; neutrophils= 7 patients, 14 samples. Fastq files provided. Whole RNA-sequencing of CD34+ cells and neutrophils derived from MPN patients before hydroxycarbamide treatment and after 9-months of treatment. CD34+ cells= 5 patients, 10 samples; neutrophils= 7 patients, 14 samples. Fastq files provided.	Illumina HiSeq 4000	16
EGAD00010001940	DNA methylation measures on neutrophils DNA methylation measures on neutrophils	Illumina MethylationEPIC BeadChip	31
EGAD00010001941	DNA methylation measures on CD34 cells DNA methylation measures on CD34 cells	Illumina MethylationEPIC BeadChip	4

Who archives the data?

Publications

Citations

Retrieving...